SCHEMBL20914271

SCHEMBL20914271

Cc1[nH]c2c(-c3ccccc3)c(C(F)(F)F)nn2c(=O)c1-c1nc2cccc(N)c2[nH]1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.39
▸ POLB P06746 3/20 0.39
▸ MEN1 O00255 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ ARF6 P62330 4/20 0.35
▸ SLC11A2 P49281 2/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ TNKS O95271 1/20 0.33
▸ WNT3A P56704 1/20 0.33
▸ TNKS2 Q9H2K2 1/20 0.33
▸ PLAT P00750 1/20 0.32
▸ ADORA2A P29274 2/20 0.32
▸ ADORA2B P29275 2/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ ADORA3 P0DMS8 1/20 0.32
▸ ADORA1 P30542 1/20 0.32
▸ BLM P54132 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914113 0.85 KDM4E (0.45) KDM4EPOLBMEN1ALDH1A1KMT2A
SCHEMBL20913938 0.85 TNKS (0.50) KDM4EPOLBALDH1A1NPC1RAB9A
SCHEMBL20913892 0.84 MEN1 (0.40) KDM4EPOLBMEN1ALDH1A1KMT2A
SCHEMBL20913971 0.82 POLB (0.45) KDM4EPOLBMEN1ALDH1A1KMT2A
SCHEMBL20914262 0.80 TNKS (0.39) KDM4EPOLBALDH1A1TNKSWNT3A
SCHEMBL20914122 0.79 KDM4E (0.43) KDM4EPOLBMEN1ALDH1A1KMT2A
SCHEMBL20914410 0.77 POLB (0.46) KDM4EPOLBMEN1ALDH1A1KMT2A
SCHEMBL20819063 0.77 POLB (0.44) KDM4EPOLBMEN1ALDH1A1KMT2A
SCHEMBL20931211 0.75 MEN1 (0.49) KDM4EPOLBMEN1ALDH1A1KMT2A
SCHEMBL20819034 0.75 POLB (0.47) KDM4EPOLBMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 KDM4E 1922/4885POLB 4311/4885MEN1 2785/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 KDM4E 1922/4885POLB 4311/4885MEN1 2785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback